This latter approach presents numerous advantages, such as (i) the possibility of overcoming tumor heterogeneity and selection of antigen-negative clones that have escaped immune responses directed to a single peptide, and (ii) the combination of HLA class I and class II restricted epitopes, thus triggering CD4+- and CD8+-mediated recognition of cancer cells (Jain, 2010; Perez et al., 2010). Here, CD8A is linked to neoplasm.